Effects of Intermittent Fasting Variations on Nutrigenomic Profile, Metabolic Parameters, Inflammation, and Body Composition in Prediabetic Patients
Prediabetes is a metabolic condition associated with increased risk of type 2 diabetes and cardiovascular disease. Intermittent fasting (IF) has emerged as a potential dietary intervention to improve metabolic health, yet comparative evidence among different IF patterns remains limited.
This randomized controlled trial aims to evaluate the effects of three intermittent fasting regimens-5:2 fasting, alternate-day fasting, and time-restricted feeding-compared with a control diet on metabolic parameters, inflammatory markers, body composition, and nutrigenomic profiles in adults with prediabetes.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Muhammad Aron Pase, MD
- 电话号码:+6285360148731
- 邮箱:aronpase@usu.ac.id
学习地点
-
-
North Sumatera
-
Medan、North Sumatera、印度尼西亚
- Department of Internal Medicine - Endocrinology Division, Faculty of Medicine, Universitas Sumatera Utara / RSUP H. Adam Malik Medan
-
接触:
- Muhammad Aron Pase, MD
- 电话号码:+6285360148731
- 邮箱:aronpase@usu.ac.id
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Patients with prediabetes, defined according to ADA criteria (fasting plasma glucose 100-125 mg/dL or 2-hour postprandial glucose 140-199 mg/dL).
- Willing to follow the fasting/diet intervention protocol for 4-6 weeks (depending on the study duration).
- Signing informed consent and willing to be randomized into one of 3 intervention groups (Monday-Thursday Fasting/5:2, Alternate-Day Fasting/ADF, or Time-Restricted Fasting/IF).
Exclusion Criteria
- Diagnosis of type 2 diabetes mellitus.
- Currently undergoing antidiabetic drug therapy (e.g., metformin, sulfonylurea, insulin).
- Has a severe chronic disease (kidney failure, liver failure, heart failure, or eating disorder).
- Pregnancy or breastfeeding.
- History of eating disorders (anorexia nervosa, bulimia nervosa, or binge eating disorder).
- Taking medications that affect glucose metabolism (e.g., systemic steroids, atypical antipsychotics, etc.). Diagnosis of type 2 diabetes
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
代谢谱
大体时间:基线、第3周和第6周
|
空腹血浆葡萄糖变化(毫克/分升)
|
基线、第3周和第6周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Lipid Profile
大体时间:Baseline and Week 6
|
Concentration Changes of Total Cholesterol
|
Baseline and Week 6
|
|
Lipid Profile
大体时间:Baseline and Week 6
|
Concentration Changes of LDL
|
Baseline and Week 6
|
|
Lipid Profile
大体时间:Baseline and Week 6
|
Concentration Changes of HDL
|
Baseline and Week 6
|
|
Lipid Profile
大体时间:Baseline and Week 6
|
Concentration Changes of Triglycerides
|
Baseline and Week 6
|
|
Nutrigenomics
大体时间:Baseline
|
Distribution of Fat Mass and Obesity-Associated gene polymorphism with Enzyme-Linked Immunosorbent Assay method
|
Baseline
|
|
Body Composition
大体时间:Baseline, Week 3, and Week 6
|
Change in BMI
|
Baseline, Week 3, and Week 6
|
|
Body Composition
大体时间:Baseline, Week 3, and Week 6
|
Change in Waist Circumference
|
Baseline, Week 3, and Week 6
|
|
Inflammation Profile
大体时间:Baseline and Week 6
|
Concentration Changes of inflammatory marker (CRP)
|
Baseline and Week 6
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- USumateraUtara Prediabetic
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.